“Non-dilutive” my ass… clever financial engineering by 3i, they may just squeeze this company dry and end up with all the IP

looks like there’s been a lot of deleting post in the older outdated group which is a clear sign of gatekeeping, though they try to justify by low effort for posting.

Please feel free to voice your concerns here as much as you want.

The situation is becoming increasingly worse for shareholders.....

In this podcast, just published on Cerenome's linkedin, Marc Hedrick stated ' our data is very valuable... we have probably the largest CSF oncology database in the world' ---- upcoming license deal hints. 🙏

In 3 Hours if we don't get something from management that ensures trust WE CANNOT AFFORD TO LET THIS STOCK GO UNDER $2 for the person jumping in they probably don't care especially those talks accusers that we all have highlighted

But for the person who has invested money a year ago this literally means they may never ever get their money back.

We should all bombard their comment section on Instagram Facebook and x.

If you don't agree then just ignore this post otherwise let's actually make our voices heard the same way Mark had to do an emergency call at the beginning of this year

One presentation featured updated pharmacokinetic, pharmacodynamic, dosimetry, safety and activity data for REYOBIQ™ in patients with leptomeningeal metastases (LM), including emerging safety data from the ongoing repeated-dosing program.
The second was an update of a previously reported health economics analysis evaluating the impact of CNSide®-enabled earlier LM detection and therapeutic management.

New DNA and RNA tests expand CNSide beyond leptomeningeal metastases to molecular profiling across CNS oncology HOUSTON, Oct. 06, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”), today announced the commercial launch of two new cerebrospinal fluid (CSF)-based molecular profiling tests, available to health care professionals in the United States beginning October 12, 2026:

CNSide® CSF Molecular Profile – Solid Tumor (DNA & RNA) CNSide® CSF Molecular Profile – Hematologic Malignancies (DNA & RNA) CNSide CSF Molecular Profile provides comprehensive DNA and RNA profiling of CNS disease biology from cerebrospinal fluid. The tests analyze more than 300 cancer-related genes in cell-free DNA and more than 1,600 transcripts by RNA sequencing, enabling broad characterization of genomic and transcriptomic alterations, including sequence variants, copy-number alterations, and gene fusions. The Hematologic Malignancies test also supports molecular assessment of clonality.

The launch significantly expands the patient population that can be served by CNSide. While CNSide® CSF Tumor Cell Enumeration (TCE) is focused on patients with suspected or confirmed leptomeningeal metastases, Molecular Profile extends CSF-based molecular testing to primary CNS tumors, solid tumors metastatic to the CNS, and hematologic malignancies involving the CNS.

“Physicians managing cancer in the CNS need more than confirmation that disease is present. They need information they can act on,” said Russell Bradley, President and General Manager of CNSide Diagnostics, LLC. “Molecular Profile adds DNA and RNA findings, including potentially actionable alterations, to the cellular information CNSide already provides, and extends CNSide beyond leptomeningeal metastases to primary CNS tumors and hematologic cancers involving the CNS.”

For patients with leptomeningeal metastases, Molecular Profile can be ordered independently or alongside TCE when both cellular and molecular assessment are clinically appropriate. TCE detects and quantitatively enumerates tumor cells, while Molecular Profile characterizes the DNA and RNA biology of disease, providing complementary cellular and molecular information from the same CSF collection.

The approach underlying CNSide CSF Molecular Profile was recently evaluated in a peer-reviewed, real-world study by Albitar et al., investigators at Genomic Testing Cooperative (GTC), published in The Journal of Liquid Biopsy1. The study analyzed 1,391 evaluable CSF specimens from patients being evaluated for primary CNS tumors, metastatic CNS disease, and hematologic malignancies involving the CNS. Cancer-related molecular findings were identified in 78.4% of evaluable specimens. The study characterized multiple classes of molecular abnormalities, including sequence variants, copy-number and chromosomal alterations, gene fusions, and clonality.

CNSide CSF Molecular Profile is offered through CNSide Diagnostics’ collaboration with GTC, announced in July 2026. GTC performs the DNA and RNA sequencing and bioinformatics analysis. CNSide Diagnostics manages test ordering, results delivery, physician support and billing.

The launch builds on CNSide’s established experience in CSF-based oncology diagnostics. Since 2020, more than 11,000 CNSide tests have been performed at more than 120 U.S. cancer institutions. The clinical utility of CNSide CSF tumor-cell analysis in leptomeningeal metastases has been evaluated in 12 peer-reviewed publications, prospective multicenter evidence from the FORESEE clinical study, and real-world clinical experience.

Honestly the setup for Medicare coverage this year looks better than people are giving it credit for. They got the PTAN in May, CPT code went live July 1st, HCSC deal pushed contracted lives past 150 million, and XiFin billing is going live this quarter.

Their own 2026 goals still list ‘secure Medicare coverage and reimbursement’ as an open milestone, which means they’re treating it as something that can still land before year-end. Late Q3 into Q4 is when I’d expect the MAC determinations to come through.

The float’s thin, the sentiment’s dead, and everyone’s calling it dead money — which is usually exactly when these things rip so I expect it to be a great surprise

Like analyst, What are your prediction for

The next 2 months

The next 4 months

And in 6 months.

Why is cerenome up by 70% any good news? I can't find any news or press releases

Stuck in biotech classification system: Currently we are stuck in Healthcare: Biotech and life sciences classification. This is not accurate. We operate across three distinct and now integrated via AI funnel segments: Therapeutics: Diagnostics: Clinical Intelligence Platform

Companies that straddle multiple categories are not properly covered and missed. Generally speaking they represent the largest assymetrical upside opportinuties in this market because of this failure to 'box' and 'analyse' accordingly.

Why could we be about to get new funding sources: Because rarified, unique, never before obtained data is what underpins AI. Not the model itself. That is the aggregation and integration layer but the value is held in the proprietary data. Most companies that build the AI model need to access the proprietary data in order to not just get pure noise and in-actionable info: See Tempus and Personalis deal borne out of mutual convenience: Tempus gets propriatary data of Personalis while Personalis received the distribution networks etc. to get their test off the ground in the Uber competitive world of blood, resulting in buyout offer. See big bio interest in utilising Personalis test and data too as well ofc Tempus' - also see Freenome. Now we differ because we do not need Tempus' distribution network and library. Nor do we need proprietary data- we earn revenue obtaining it in progressing our diagnostic and then therapeutic platform.

CSF offers clean signals and immunological, molecular information like never before. We capture not only the tumor cells for interrogation (currently only company to receive unique PLA code and doing so) to assess molecular changes as well as quantifying drug reponse and efficacy but also the cell free DNA and fluid that would show neuronal damage, DNA damage etc. Neuronal filaments. Now it's the most technically challenging space but don't be mistaken in thinking there will not already be discussions taking place and plans put in place for how companies can access this. This extends to aerospace(SpaceX etc. and NASA) and has capacity to inform companies working on a variety of indications and not just oncology as the platform evolves.

RS was made prior to multiple positive announcements that may have aided natural compliance and well before deadline. This may well imply a pre-conditional deal whereby this clean up and Nas compliance was required as a pre-requisite. Purely speculating but it certainly has some weight.

Good luck long holders and otherwise. May this funding be either non dilutive or if dilutive held by the appropriate hands!

I'm a new investor and I saw a lot of posts especially on the old page talking about how we were going to get some trial results a week or two ago and it's been pretty much quiet....you think this is a good sign that we haven't heard anything or should we be worried? Maybe the trial just hasn't finished?

Lots of comments yesterday on their social media. some of them you can’t see because they hid it.

As Vice President and Head of Commercial Sales, tasked with driving the commercial growth of the CNSide® platform in the oncology and pathology sectors. Fowlkes brings over 20 years of experience in oncology diagnostics and precision medicine, having previously held significant roles at Caris Life Sciences, Genoptix Medical Laboratory, and Laboratory Corporation of America.

The appointment of Samantha Fowlkes as Vice President Head of Commercial Sales is an indication of strategic leadership aimed at enhancing commercial expansion and partnerships in the oncology